AEON Biopharma (AEON) Interest & Investment Income (2021 - 2023)

AEON Biopharma has reported Interest & Investment Income for 3 years, with the latest figure at $199960.0 in Q2 2023.

• Quarterly Interest & Investment Income rose 45.55% year-over-year to $199960.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $5.3 million (up 1625.36% YoY) and the FY2022 annual result came in at $3.7 million, up 4551.53% from the prior year.
• Interest & Investment Income fell to $199960.0 in Q2 2023 per AEON's latest filing, from $1.7 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $2.3 million in Q4 2022 and troughed at $8319.0 in Q1 2021.
• A 3-year average of $568868.3 and a median of $133483.0 in 2022 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2023: Interest & Investment Income jumped 10685.58% in 2022, then surged 45.55% in 2023.
• Over 3 years, Interest & Investment Income stood at $21218.0 in 2021, then surged by 10685.58% to $2.3 million in 2022, then plunged by 91.26% to $199960.0 in 2023.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $199960.0, $1.7 million, and $2.3 million for Q2 2023, Q1 2023, and Q4 2022 respectively.